{"id":46338,"date":"2025-11-11T13:07:59","date_gmt":"2025-11-11T05:07:59","guid":{"rendered":"https:\/\/flcube.com\/?p=46338"},"modified":"2025-11-11T13:08:00","modified_gmt":"2025-11-11T05:08:00","slug":"simcere-launches-phase-ii-trial-of-t%e2%80%91reg%e2%80%91selective-il%e2%80%912-fusion-sim0278-for-moderate%e2%80%91to%e2%80%91severe-atopic-dermatitis-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46338","title":{"rendered":"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China"},"content":{"rendered":"\n<p><strong>Simcere Pharmaceutical Group Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2096:HKG\">HKG: 2096<\/a>) announced that the <strong>Phase\u202fII clinical study<\/strong> of its proprietary <strong>Regulatory\u2011T\u2011cell\u2011preferential IL\u20112 mutant\u2011Fc fusion protein (SIM0278)<\/strong> has officially begun in mainland China. The trial targets patients with <strong>moderate\u2011to\u2011severe atopic dermatitis (AD)<\/strong> and marks the first late\u2011stage evaluation of Simcere\u2019s <strong>Treg\u2011biased cytokine platform<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-amp-development-milestones\">Deal &amp; Development Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Initiation<\/strong><\/td><td>Phase\u202fII, multicenter, double\u2011blind, placebo\u2011controlled trial in China (N\u2248120)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate\u2011to\u2011severe atopic dermatitis (EASI \u2265\u202f16)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>SIM0278 \u2013 IL\u20112 mu\u2011Fc fusion protein engineered for <strong>Treg\u2011selective activation<\/strong><\/td><\/tr><tr><td><strong>Mechanistic Advantage<\/strong><\/td><td>Mutations reduce affinity for effector T cells &amp; NK cells while preserving high affinity for CD25\u207a Tregs<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>Almirall\u202fS.A. (exclusive rights outside Greater China)<\/td><\/tr><tr><td><strong>Previous Clinical Data<\/strong><\/td><td>Phase\u202fI completed in the U.S. (Almirall) \u2013 favorable safety, PK profile<\/td><\/tr><tr><td><strong>Future Plans<\/strong><\/td><td>Almirall to start a Phase\u202fII trial in a separate dermatologic disease (Q1\u202f2026)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Simcere Pharmaceutical Group Ltd. (HKEX:\u202f2096)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>10\u202fNov\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-rationale\">Scientific Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treg\u2011Preferential IL\u20112 Mutant (IL\u20112\u202fmu\u2011Fc):<\/strong> Engineered to <strong>lower binding to CD122\/CD132<\/strong> (effector T\u2011cell\/NK receptors) while <strong>maintaining high affinity for CD25<\/strong> on regulatory T cells.<\/li>\n\n\n\n<li><strong>Immune\u2011Modulation:<\/strong> Selective Treg expansion restores <strong>immune homeostasis<\/strong> without suppressing protective effector responses, a novel approach for <strong>immune\u2011mediated skin disorders<\/strong>.<\/li>\n\n\n\n<li><strong>Pre\u2011clinical Evidence:<\/strong> Demonstrated <strong>\u2265\u202f5\u2011fold increase<\/strong> in Treg numbers and <strong>significant reduction<\/strong> in skin inflammation in AD mouse models.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-competitive-landscape\">Market &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atopic Dermatitis Burden:<\/strong> Over <strong>15\u202fmillion<\/strong> patients in China; market projected to exceed <strong>CNY\u202f30\u202fbillion<\/strong> by 2028.<\/li>\n\n\n\n<li><strong>Current Therapies:<\/strong> Topical steroids, dupilumab, JAK inhibitors \u2013 all carry safety or adherence challenges.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> SIM0278 offers <strong>oral\u2011like convenience<\/strong> (subcutaneous injection), <strong>Treg\u2011specific action<\/strong>, and a <strong>potentially safer profile<\/strong> compared with broad immunosuppressants.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-strategic-implications\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Funding:<\/strong> Simcere has allocated <strong>CNY\u202f500\u202fmillion<\/strong> (\u2248\u202fUS$70\u202fmillion) to support the Phase\u202fII program and subsequent global development.<\/li>\n\n\n\n<li><strong>Share Reaction:<\/strong> Hong\u202fKong\u2011listed shares rose <strong>\u2248\u202f3.8\u202f%<\/strong> in early trading, reflecting investor optimism around the novel modality.<\/li>\n\n\n\n<li><strong>Partnership Leverage:<\/strong> The <strong>Almirall<\/strong> agreement grants Simcere a <strong>China\u2011centric commercial runway<\/strong> while providing Almirall access to <strong>global markets<\/strong> (Europe, North America, LATAM).<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Simcere\u2019s Phase\u202fII trial timeline, regulatory expectations, and commercial potential of SIM0278. Actual results may differ due to risks including clinical outcomes, regulatory approvals, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase\u202fII clinical study of its proprietary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,1099,271],"class_list":["post-46338","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-hkg-2096","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase\u202fII clinical study of its proprietary Regulatory\u2011T\u2011cell\u2011preferential IL\u20112 mutant\u2011Fc fusion protein (SIM0278) has officially begun in mainland China. The trial targets patients with moderate\u2011to\u2011severe atopic dermatitis (AD) and marks the first late\u2011stage evaluation of Simcere\u2019s Treg\u2011biased cytokine platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46338\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase\u202fII clinical study of its proprietary Regulatory\u2011T\u2011cell\u2011preferential IL\u20112 mutant\u2011Fc fusion protein (SIM0278) has officially begun in mainland China. The trial targets patients with moderate\u2011to\u2011severe atopic dermatitis (AD) and marks the first late\u2011stage evaluation of Simcere\u2019s Treg\u2011biased cytokine platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46338\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T05:07:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T05:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1108.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China\",\"datePublished\":\"2025-11-11T05:07:59+00:00\",\"dateModified\":\"2025-11-11T05:08:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338\"},\"wordCount\":412,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1108.webp\",\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2096\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46338#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46338\",\"name\":\"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1108.webp\",\"datePublished\":\"2025-11-11T05:07:59+00:00\",\"dateModified\":\"2025-11-11T05:08:00+00:00\",\"description\":\"Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase\u202fII clinical study of its proprietary Regulatory\u2011T\u2011cell\u2011preferential IL\u20112 mutant\u2011Fc fusion protein (SIM0278) has officially begun in mainland China. The trial targets patients with moderate\u2011to\u2011severe atopic dermatitis (AD) and marks the first late\u2011stage evaluation of Simcere\u2019s Treg\u2011biased cytokine platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46338\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1108.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1108.webp\",\"width\":1080,\"height\":608,\"caption\":\"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46338#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase\u202fII clinical study of its proprietary Regulatory\u2011T\u2011cell\u2011preferential IL\u20112 mutant\u2011Fc fusion protein (SIM0278) has officially begun in mainland China. The trial targets patients with moderate\u2011to\u2011severe atopic dermatitis (AD) and marks the first late\u2011stage evaluation of Simcere\u2019s Treg\u2011biased cytokine platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46338","og_locale":"en_US","og_type":"article","og_title":"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China","og_description":"Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase\u202fII clinical study of its proprietary Regulatory\u2011T\u2011cell\u2011preferential IL\u20112 mutant\u2011Fc fusion protein (SIM0278) has officially begun in mainland China. The trial targets patients with moderate\u2011to\u2011severe atopic dermatitis (AD) and marks the first late\u2011stage evaluation of Simcere\u2019s Treg\u2011biased cytokine platform.","og_url":"https:\/\/flcube.com\/?p=46338","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-11T05:07:59+00:00","article_modified_time":"2025-11-11T05:08:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1108.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46338#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46338"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China","datePublished":"2025-11-11T05:07:59+00:00","dateModified":"2025-11-11T05:08:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46338"},"wordCount":412,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46338#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1108.webp","keywords":["Auto-immune","Clinical trial approval \/ initiation","HKG: 2096","Simcere Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46338#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46338","url":"https:\/\/flcube.com\/?p=46338","name":"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46338#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46338#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1108.webp","datePublished":"2025-11-11T05:07:59+00:00","dateModified":"2025-11-11T05:08:00+00:00","description":"Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase\u202fII clinical study of its proprietary Regulatory\u2011T\u2011cell\u2011preferential IL\u20112 mutant\u2011Fc fusion protein (SIM0278) has officially begun in mainland China. The trial targets patients with moderate\u2011to\u2011severe atopic dermatitis (AD) and marks the first late\u2011stage evaluation of Simcere\u2019s Treg\u2011biased cytokine platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46338#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46338"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46338#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1108.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1108.webp","width":1080,"height":608,"caption":"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46338#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Launches Phase\u202fII Trial of T\u2011Reg\u2011Selective IL\u20112 Fusion (SIM0278) for Moderate\u2011to\u2011Severe Atopic Dermatitis in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1108.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46338"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46338\/revisions"}],"predecessor-version":[{"id":46341,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46338\/revisions\/46341"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46340"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}